Bridger Management LLC Invests $4.66 Million in HealthEquity, Inc. $HQY

Bridger Management LLC bought a new position in shares of HealthEquity, Inc. (NASDAQ:HQY) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 51,616 shares of the company’s stock, valued at approximately $4,662,000. HealthEquity comprises 3.1% of Bridger Management LLC’s portfolio, making the stock its 14th biggest position.

Several other institutional investors also recently bought and sold shares of HQY. Acumen Wealth Advisors LLC bought a new stake in HealthEquity in the 4th quarter valued at $27,000. Caitong International Asset Management Co. Ltd boosted its holdings in shares of HealthEquity by 1,723.5% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $28,000 after purchasing an additional 293 shares during the last quarter. Aster Capital Management DIFC Ltd purchased a new position in shares of HealthEquity during the fourth quarter valued at about $28,000. Leonteq Securities AG grew its position in shares of HealthEquity by 159.9% during the first quarter. Leonteq Securities AG now owns 382 shares of the company’s stock valued at $32,000 after purchasing an additional 235 shares in the last quarter. Finally, Axiom Investment Management LLC bought a new stake in shares of HealthEquity in the first quarter worth about $33,000. 99.55% of the stock is owned by hedge funds and other institutional investors.

HealthEquity News Roundup

Here are the key news stories impacting HealthEquity this week:

• Positive Sentiment: HealthEquity exceeded expectations with adjusted earnings of $1.24 per share versus the $1.19 consensus, while revenue reached $350.7 million, slightly above estimates. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Profitability improved, with net income rising 10% to $65.6 million and net margin expanding to 19% from 18%. Adjusted EBITDA grew 11% to $167 million, while its margin increased to 48% from 46%. HealthEquity Second-Quarter Financial Results
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. Record HSA assets of $37.9 billion provide additional support for the company’s long-term growth outlook. HealthEquity Raises Fiscal 2027 Guidance
• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and raised its price target to $115. Another analysis indicated that HQY could be approximately 19% undervalued after the guidance increase, reinforcing the bullish interpretation of the earnings update. BTIG Research Rating HealthEquity Could Be Undervalued
• Neutral Sentiment: Fiscal 2027 revenue guidance of approximately $1.4 billion was broadly in line with expectations, so the guidance improvement was driven mainly by stronger anticipated earnings and margins.
• Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares valued at approximately $798,000, reducing his position by 10.9%. The sale was executed under a pre-arranged Rule 10b5-1 plan, which reduces its negative signaling value but could still attract investor attention. HealthEquity Director Stock Sale
• Negative Sentiment: HQY trades at a premium valuation of roughly 35 times earnings. After the recent advance toward its 52-week high, some investors may lock in gains, potentially tempering the stock’s reaction to otherwise favorable fundamentals.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Citizens Jmp boosted their target price on HealthEquity from $110.00 to $111.00 and gave the stock a “market outperform” rating in a research report on Monday, June 1st. Wall Street Zen raised HealthEquity from a “hold” rating to a “buy” rating in a research note on Saturday, August 22nd. Wells Fargo & Company set a $111.00 price objective on HealthEquity in a report on Monday, June 1st. BTIG Research reiterated a “buy” rating and set a $115.00 target price on shares of HealthEquity in a research report on Friday. Finally, Royal Bank Of Canada raised their target price on shares of HealthEquity from $100.00 to $108.00 and gave the company an “outperform” rating in a report on Wednesday, June 3rd. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $110.93.

HealthEquity Stock Up 3.2%

Shares of NASDAQ:HQY opened at $96.37 on Friday. The company has a current ratio of 2.99, a quick ratio of 3.44 and a debt-to-equity ratio of 0.47. HealthEquity, Inc. has a 12 month low of $72.76 and a 12 month high of $107.62. The company has a 50-day moving average price of $98.16 and a 200 day moving average price of $87.87. The company has a market cap of $8.06 billion, a price-to-earnings ratio of 34.79, a PEG ratio of 1.57 and a beta of 0.21.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Thursday, August 27th. The company reported $1.24 EPS for the quarter, topping the consensus estimate of $1.19 by $0.05. HealthEquity had a return on equity of 15.33% and a net margin of 17.36%.The company had revenue of $350.73 million during the quarter, compared to analyst estimates of $349.22 million. The company’s quarterly revenue was up 95.5% on a year-over-year basis. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. As a group, equities research analysts predict that HealthEquity, Inc. will post 3.92 earnings per share for the current year.

Insider Buying and Selling

In other news, EVP Michael Henry Fiore sold 2,470 shares of HealthEquity stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $95.00, for a total value of $234,650.00. Following the completion of the transaction, the executive vice president owned 56,643 shares in the company, valued at approximately $5,381,085. The trade was a 4.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian T. Dillon sold 7,632 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $104.61, for a total value of $798,383.52. Following the transaction, the director directly owned 62,395 shares in the company, valued at approximately $6,527,140.95. This represents a 10.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 12,456 shares of company stock valued at $1,256,664. Company insiders own 1.60% of the company’s stock.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.